Antiviral Tamiflu loses power; Crucell reports profit; new AIDS vaccine in Phase I;

Vaccine market

The antiviral Tamiflu no longer works against the most dominant flu strain in circulation, according to government officials. And that could have a significant impact on the way the country prepares for an eventual pandemic. Report

Only one in four young black females have received the HPV vaccine shot, even though a large percentage of the target population has a positive view of the protection it offers. Story

Crucell reported a net profit in 2008 of €14.6 million, compared  to a net loss of €42.9 million in 2007. Report

Researchers have catalogued the numerous research studies that conclude there is no link between vaccines and autism. Story

Vaccine Research

The Indian Council of Medical Research will start phase I clinical trials to test a combination of two AIDS vaccine candidates. Story

Researchers from George Mason University, the University of Hong Kong, Guangzhou Children's Hospital, the South China Institute of Technology and the Graduate School of Chinese Academy of Sciences have developed a DNA-based vaccine that has effectively protected mice from the adenovirus-3 infection. Release

Vietnamese scientists say they are moving to the second phase of clinical testing of a new H5N1 vaccine. Report

GlaxoSmithKline and the Bioprocessing Technology Institute in Singapore have inked a deal to partner on vaccine and adjuvant research. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.